Upcoming DCAT European Conference: Expedition Pharma: Innovation from a Patient-First Perspective   

How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

How is innovation inspiring and fueling the transformation of the bio/pharma industry? DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

DCAT’s European conference and networking event  
In 2024, the Drug, Chemical & Associated Technologies Association (DCAT) achieved a significant milestone in its 134-year history by hosting its first education and networking event outside the US.  Responding to the needs of its diverse membership—over half of whom are headquartered outside the US—the Summit at Lugano brought together global thought leaders across all disciplines to address the topic of sustainability. This inaugural event was met with overwhelming support from all avenues of the bio/pharma industry. On the heels of that outstanding reception, DCAT will return to the picturesque city of Lugano, Switzerland, June 4-5, 2025, for its conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective

The diverse and complex nature of the bio/pharma industry continues to face new challenges from all directions, and there is little doubt that conversations from manufacturing, scientific and technical meetings by staff and operations, up to the Board of Directors and back again, are defining business strategies and tactical programs centered on true innovation, differentiation, adaptability, and long-term profitably to gain a competitive advantage. These are fundamental to survival, let alone growth. As the premier organization for building and maintaining significant networking relationships, DCAT is bringing this conversation to a global audience for those who value vigorous discussions and alternative perspectives and are open to sharing their learning experiences—successes and setbacks. 

Innovation is the lifeblood of the bio/pharma industry, not only in terms of new product development but also in how the industry adapts its manufacturing and supply-chain operations to respond to a changing marketplace. The question behind all of this is perspective and purpose—is it a patient-first mindset that drives breakthroughs in research, process optimization, quality assurance, and building a robust and resilient supply chain at the core of decision-making in your organization?  Expedition Pharma will be a novel opportunity to explore this in a collegial and energetic environment with many of the industry’s leading-edge organizations.  

Expedition Pharma: Innovation from a Patient-First Perspective, hosted by DCAT, will feature innovation makers from across the global bio/pharma industry to share practical and concrete ways in which their companies have worked to improve patient care and health outcomes.  The two-day event will be held June 4–5, 2025, in Lugano, Switzerland. It will bring to the forefront the challenges being faced and highlight practical strategies and actions taken by bio/pharma companies and suppliers on an individual company basis and in collaboration with others.  

Call for Presentations: Share Your Insights 
DCAT Member Companies, non-members, and industry thought leaders are invited to apply and present their innovative approaches and solutions at Expedition Pharma: Innovation from a Patient-First Perspective, a DCAT educational and networking event on June 4–5, 2025, in Lugano, Switzerland. Applications are due February 28, 2025, and should address one or more of the following areas:

  • Improving product availability through mitigating drug shortages and supply-chain disruptions or enhancing production scalability  
  • New drug pricing models and improving market access  
  • Sustainability initiatives in R&D, manufacturing, and supply chains 
  • Data and technology-driven solutions, such as AI or predictive analytics, to enhance R&D productivity, streamline manufacturing, or improve patient care  
  • Advancements in quality control/assurance and safety protocols in manufacturing  
  • New metrics, investments, and business practices across development, manufacturing, and the supply chain, resulting in improved patient outcomes.   

Expedition Pharma is an opportunity to network with global leaders and colleagues across industry disciplines. Be a part of meaningful discussions, idea exchanges, and fostering partnerships that innovate, inspire and transform from a patient-first perspective.  

Register Today 
Be a part of the event that is shaping the future of the bio/pharma industry. Expedition Pharma offers an unparalleled platform for innovation, collaboration, and growth. Further information on DCAT’s Expedition Pharma: Innovation from a Patient-First Perspective may be found here, including how to apply to present or register to attend.   

Recent Feature Articles

CDMO Insights: What’s Trending in the Injectable Drug Market?

By
GPL-1s for treating Type 2 diabetes and obesity have been a key growth driver for the bio/pharma industry as well as for CDMOs of injectables, but will the entry of oral GLP-1s and related drugs put a damper on growth prospects for injectables? What is the expected market penetration?

Pharma Customer–Supplier Insights: What Constitutes Value Creation?

By
Delivering value beyond product and price is crucial for CDMOs and suppliers to gain a competitive edge with their bio/pharma customers, but are the buy and sell side aligned in what constitutes value? The latest DCAT Benchmarking & Research study provides key insights.

Small-Molecule CDMO Outlook: What Lies Ahead

By
At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing

Biotech IPOs: Who Is Topping the Class of 2026?

By
What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…